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Epigenetic drugs like histone deacetylase inhibitors (HDACi) and DNA-methyltransferase
inhibitors (DNMTi) have been shown to be effective against a variety of tumor enti-
ties. Among different molecular anticancer activities of epigenetic active substances,
up-regulation of natural killer (NK) cell ligands was described to contribute to an enhanced
NK cell-mediated killing of tumor cell lines. So far, no data is available on this effect in child-
hood acute lymphoblastic leukemia. We investigated the effect of two HDACi [vorinostat,
valproic acid (VPA)] and two DNMTi (azacytidine, decitabine) on the viability, expression
of NK ligands, and NK susceptibility of the pre-B-cell-ALL cell line MHH-CALL-4. Whereas
vorinostat, azacytidine, and decitabine directly reduced viability of the cell line, VPA had
no direct cytotoxic effect. NKG2D-ligands were expressed only at very low levels and not
affected by epigenetic treatment. Higher expression was found for the DNAM-1 ligands
with significant up regulation of CD112 after treatment with VPA (p=0.02). No significant
increase in lysis mediated by resting NK cells could be observed, whereas incubation of
target cells with decitabine resulted in a significant increase in lysis mediated by IL-2 acti-
vated NK cells (p=0.0051, p=0.06 for azacytidine). Vorinostat and VPA could increase
the lysis by expanded NK cells which was statistically not significant due to high inter-
individual variability. Furthermore, HDACi but not DNMTi reduced the NK-mediated lysis of
MHH-CALL-4 after incubation of effector cells. In conclusion, there is a synergistic effect
between epigenetic drugs and NK cells against MHH-CALL-4 which is not as strong as in
other tumor entities. In situations where NK-mediated control of leukemia is assumed or
wanted, a sophisticated combination of single epigenetic drugs and ex vivo expanded NK
cells is needed to maximize the synergistic effect of both treatment strategies and DNMTIs
may be preferred based on the direct inhibitory effect of HDACi on NK cell cytotoxicity.
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INTRODUCTION
Children with leukemia relapse after conventional chemotherapy
still have a poor prognosis and will profit from stem cell transplan-
tation (SCT). For patients without a family or matched unrelated
donor haploidentical SCT from mismatched related donors has
become an established procedure for the treatment of children
with high risk and relapsed leukemia (Handgretinger et al., 2001;
Lang et al., 2003; Marks et al., 2006). However, relapse after trans-
plantation still represents a major problem. Natural killer (NK)
cells are the lymphocyte subset showing the fastest reconstitution
in vivo. Therefore, NK cells are the predominant lymphocyte sub-
set which may exert antileukemic effects early after haploidentical
SCT due to delayed reconstitution of a functional T cell reper-
toire. Indeed, NK cells have been shown to mediate antileukemic
effects after haploidentical transplantation in adults with AML
and children with ALL (Ruggeri et al., 2002; Leung et al., 2004).
The function of NK cells is thereby regulated by the balance of
activating and inhibitory signals transmitted by different cell sur-
face receptors (Moretta et al., 2001; Lanier, 2005). One of the
most important factors influencing NK-mediated lysis of pedi-
atric ALL cells is the level of HLA class I molecules expressed by
the leukemic cells (Pfeiffer et al., 2007). Strong HLA class I expres-
sion can engage inhibitory NK cell receptors which dampen signals
transduced through activating receptors, whereas down regula-
tion of HLA class I can render cells to valid targets for lysis by
NK cells. Another way to overcome HLA class I mediated protec-
tion from lysis is the augmentation of activating signals. This can
be achieved by activation of NK cells through cytokines which
can lead to up-regulation of activating receptors like NGK2D
or DNAM-1 or by up-regulation of ligands for activating NK
receptors on leukemic cells. Epigenetic drugs like histone deacety-
lase inhibitors (HDACi) and DNA-methyltransferase inhibitors
(DNMTi) have been shown to be effective against a variety of
tumor entities. Among different molecular anticancer activities of
epigenetic active substances an up-regulation of NK cell ligands
was described for the HDACi valproic acid (VPA), suberoylanilide
hydroxamic acid (SAHA, vorinostat), trichostatin A (TSA), and
the DNMTi 5-aza-2′-deoxycytidine (decitabine), contributing to
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an enhanced NK cell-mediated killing of the different tumor enti-
ties (Rohner et al., 2007; Diermayr et al., 2008; López-Soto et al.,
2009; Chávez-Blanco et al., 2011). Combination of activated and
expanded NK cells with epigenetic drugs, which both have antitu-
mor effects on their own, should result in a synergistic effect and
a promising addition to conventional therapy and may enhance
the NK-mediated anti leukemic effect after haploidentical trans-
plantation. Therefore, we investigated the influence of the HDACi
VPA and vorinostat and the DNMTi 5-azacytidine (Vidaza®) and
5-aza-2′-deoxycytidine (decitabine) on the cytotoxic function of
NK cells, on the viability of the B-lineage acute lymphoblastic
leukemia cell line MHH-CALL-4 and on the NK susceptibility of
this cell line against resting and activated NK cells.
MATERIALS AND METHODS
CELL LINES
MHH-CALL-4 and K562 cells were obtained from the Leibniz
Institute DSMZ-German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany). K562mb15-41BBL cells were
kindly provided by Dario Campana, St. Jude Children’s Research
Hospital, Memphis, TN, USA). MHH-CALL-4 cells were cultured
in RPMI 1640 supplemented with 20% FCS (both from Biochrom
AG, Berlin, Germany), K562 were cultured in RPMI 1640 sup-
plemented with 10% FCS and K562mb15-41BBL in RPMI 1640
supplemented with 10% human AB-serum (obtained from the
Institute for Clinical and Experimental Transfusion Medicine,
Tuebingen, Germany).
HDACi AND DNMTi
Vorinostat was kindly provided by MSD Sharp & Dohme GmbH,
Haar, Germany. VPA was used from Desitin Arzneimittel GmbH
(Hamburg, Germany). 5-Azacytidine and 5-aza-2′-deoxycytidine
were obtained from Sigma Aldrich (Munich, Germany). HDACi
and DNMTi were used in different concentrations, indicated in
the different experiments. Target or effector cells were incubated
for 48 h with HDACi or DNMTi before testing.
VIABILITY ASSAY
The Cell Titer 96® AQueous One Solution Cell Proliferation
(MTS) Assay (Promega, Mannheim, Germany) was used to mea-
sure cell viability via redox enzyme activity, according to the
protocol provided by the manufacturer. MHH-CALL-4 cells
(100,000 cells/well) in the exponential growth phase were grown
in 96-well plates. The day after seeding, the cells were incubated
in the presence of HDACi or DNMTi for another 48 h at 37˚C in a
humidified atmosphere of 5% CO2 in air. At the end of the incu-
bation period, MTS reagent (20µl) was added to the wells, and
the plate was incubated for 1 h protected from light. Absorbance
was recorded at 490 nm using the Victor™1420 multilabel counter
(Wallac,Rodgau,Germany). A reference wavelength of 630 nm was
used to subtract background by excess cell debris or other non-
specific absorbance. Wells containing the appropriate medium
without cells served as blank.
FLOW CYTOMETRY
The following mAbs were used for flow cytometry: mouse IgG1
unconjugated, goat-anti-mouse-PE (Becton-Dickinson, Heidel-
berg, Germany), anti-MICA, anti-MICB unconjugated (kindly
provided by Prof. Steinle, Institute for Molecular Medicine, Frank-
furt am Main, Germany), anti-MICA/B APC, anti-CD112 PE
(BioLegend, San Diego, CA, USA), anti-ULBP1 (Z-9), anti-ULBP2
(F16), anti-ULBP3 (2F9), anti-ULBP4 (6E6) (Santa Cruz Biotech-
nology, Dallas, TX, USA), anti-CD155 (eBioscience, San Diego,
CA, USA), propidium iodide solution (Sigma Aldrich, Munich,
Germany). Samples were analyzed on a FACSCalibur flow cytome-
ter (Becton-Dickinson, Heidelberg, Germany) using CELLQUEST
software (BD). A minimum of 20,000 events was used for
assessment.
ISOLATION AND EXPANSION OF NK CELLS
Peripheral mononuclear cells (PMNC) from healthy donors
were isolated by Ficoll–Hypaque density gradient centrifuga-
tion. Cells were enriched for CD56+ cells using CD56+ beads
(Miltenyi Biotec, Bergisch–Gladbach, Germany) according to the
manufacturer’s instructions. For expansion PMNC were incu-
bated with irradiated (100 Gy) K562mb15-41BBL cells at a ratio
of 1:1.5 in RPMI 1640 supplemented with 10% human AB-
serum, l-glutamine, and 100 IU/ml interleukin-2 (Proleukin,
Novartis, Basel, Suisse). Medium was exchanged every 2–
3 days with fresh medium containing IL-2. Cells were cultured
for 14 days.
CYTOTOXICITY ASSAY
Cytolytic activity of NK cells was tested in a 2-h BATDA [bis (ace-
toxymethyl) 2,2′:6′,2′-terpyridine-6,6′′-dicarboxylate] europium
release assay (Perkin Elmer, MA, USA). K562 and MHH-CALL-4
cells were used as target cells. Four different effector-to-target cell
ratios were tested. Specific lysis was calculated as follows: % specific
lysis= (experimental release− spontaneous release)/(maximum
release− spontaneous release)× 100.
FIGURE 1 | Influence of HDACi and DNMTi on viability of MHH-CALL-4.
Incubation with vorinostat, decitabine, and azacytidine resulted in significant
dose dependent reductions of cell viability whereas no reduction could be
observed after incubation with valproic acid. Shown are mean values of
absorbance ratio (absorbance of treated cells/absorbance of untreated
cells) and standard deviation (n=3 for vorinostat, n=6 for valproic acid,
n=4 for decitabine and azacytidine, *p<0.05, **p<0.01, ***p<0.005).
Frontiers in Oncology | Pediatric Oncology April 2013 | Volume 3 | Article 99 | 2
Pfeiffer et al. HDACi, DNMTi, NK cell cytotoxicity
FIGURE 2 | Continued
FIGURE 2 | Influence of HDACi and DNMTi on NK ligand expression of
MHH-CALL-4. Mean fluorescence intensity (MFI) was measured by FACS
analysis and a MFI ratio (MFI with specific mAb/MFI with control mAb) was
calculated. Shown are mean values and standard deviation [(A) vorinostate,
n=7; (B) valproic acid, n= 8; (C) decitabine, n=4; (D) azacytidine, n=4].
MHH-CALL-4 cells did not express ligands for NKG2D or only at very low
levels. Higher expression was found for the DNAM-ligands CD112 and
CD155 which were slightly up regulated by HDACi and not or only to a
lower extend by DNMTi (*p< 0.05).
STATISTICAL ANALYSIS
Student’s t -tests were performed using GraphPad Prism version
4.01 for Windows, GraphPad Software, San Diego, CA, USA,
www.graphpad.com.
RESULTS
INFLUENCE OF HDACi AND DNMTi ON VIABILITY OF MHH-CALL-4
To test the direct effect of HDACi and DNMTi on the viability
of the MHH-CALL-4 MTS assays were performed. Absorbance
at 490 nm was measured after 1 and 3 h. Figure 1 shows the
results of the measurement after 1 h. A significant reduction of
viability could be observed after incubation with vorinostat (t -
test, p= 0.002 for 2µM), decitabine (p< 0.0001 for 2µM), and
azacytidine (p= 0.0031 for 10µM) in a dose dependent man-
ner. In contrary, VPA had no direct effect on the viability of the
MHH-CALL-4 cells.
INFLUENCE OF HDACi AND DNMTi ON EXPRESSION OF NK LIGANDS
ON MHH-CALL-4
Histone deacetylase inhibitors have been described to up regulate
the expression of ligands for activating NK receptors on different
tumor entities. We analyzed the expression of the NKG2D-ligands
MIC A, MIC B, ULBP1-4, and the DNAM-1 ligands CD112 and
CD155 before and after incubation of MHH-CALL-4 cells with
different concentrations of HDACi and DNMTi. Whereas the
cells were negative or only low positive for the NKG2D-ligands,
higher expression was found for the two DNAM-1 ligands CD112
and CD155 (Figure 2). Incubation with HDACi resulted in an
increased expression of CD112, which reached a significant level
only after incubation with VPA (t -test, p= 0.02 for 1 mM VPA,
p= 0.22 for 2µM vorinostat). DNMTi showed a different pattern
without significant differences to the untreated control (p= 0.26
for 2µM decitabine, p= 0.67 for 1 mM azacytidine). Expression
of NKG2D-ligands on MHH-CALL-4 cells was not significantly
changed by any of the tested substances.
INFLUENCE OF HDACi AND DNMTi ON NK SUSCEPTIBILITY OF
MHH-CALL-4
Histone deacetylase inhibitors have been described to sensitize dif-
ferent tumor cell lines to a NK-mediated cell lysis by up-regulation
of activating ligands. We tested cytotoxic activity of NK cells from
healthy donors against pretreated MHH-CALL-4 cells. Incuba-
tion of the target cells with vorinostat resulted in the strongest
increase in specific lysis by resting NK cells, which was statisti-
cally not significant due to a high variability between different
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FIGURE 3 | Influence of HDACi and DNMTi on NK susceptibility of
MHH-CALL-4 cells. Leukemic cells were incubated with the indicated
concentrations of HDACi and DNMTi for 48 h. Resting NK cells (A) or IL-2
stimulated NK cells (B) were used as effector cells. A lysis-ratio was
calculated from each experiment as following: specific lysis with
HDACi/DNMTi/specific lysis without HDACi/DNMTi. Shown are mean values
and standard deviation from an effector-to-target cell ratio of 20:1 [n=6 for
vorinostat (four different donors), n=15 for valproic acid (six different
donors), n= 7 for decitabine (four different donors), n=4 for azacytidine
(four different donors), **p<0.01].
donors and different experiments (n= 0.14 for 2 mM, p= 0.39 for
1µM, p= 0.37 for 0.5µM, Figure 3A). Incubation with VPA and
DNMTi led to a smaller increase in specific lysis which also did
not reach statistically significant levels (p= 0.65 for VPA 1 mM,
p= 0.11 for decitabine 2µM, p= 0.17 for azacytidine 10 µM).
Stimulation with IL-2 led to a lower variability between different
donors and lower standard deviation (Figure 3B). Statistically sig-
nificant differences were observed after incubation with decitabine
(p= 0.0051 for 2µM, p= 0.08 for 1µM). After incubation with
azacytidine the increase was not statistically significant, which
could be due to the smaller number of experiments (p= 0.06 for
10µM). Finally, in vitro expanded NK cells were used against target
cells pretreated with HDACi (Figure 4). A clear increase in cell lysis
after incubation with HDACi could be observed with these effector
cells but was not statistically significant due to the small number
of experiments and high variability between different donors.
INFLUENCE OF HDACi AND DNMTi ON NK CELL ACTIVITY
To test the direct effect of HDACi and DNMTi on cytotoxic func-
tion of NK cells, effector cells were pretreated with HDACi and
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FIGURE 4 | HDACi can sensitize the MHH-CALL-4 cell line to lysis by expanded NK cells. Leukemic cells were incubated with vorinostat or valproic acid for
48 h. Afterward, cytotoxicity assays were performed with in vitro expanded NK cells. Shown are mean values and standard deviation (n= 3).
DNMTi and tested in cytotoxicity assays against untreated K562
and MHH-CALL-4 (Figure 5). Both HDACi reduced the cytotoxic
capacity of the NK cells against K562 and MHH-CALL-4 with
a stronger and significant reduction after incubation with VPA
(E:T= 20:1, p= 0.0002 for K562, p= 0.008 for MHH-CALL-4).
DNMTi did not significantly alter NK activity against both K562
and MHH-CALL-4 cells. Furthermore, incubation with HDACi
reduced the expression of NKG2D, NKp30, and NKp46, while
incubation with DNMTi did not affect the expression of these
receptors (data not shown).
DISCUSSION
Histone deacetylase inhibitors and DNMTi showed a direct cyto-
toxic effect on MHH-CALL-4 cells with exception of VPA. In
other studies, VPA also showed a direct effect against different
human leukemia cell lines (Kawagoe et al., 2002; Sakajiri et al.,
2005). Taken together, there is concordant evidence that HDACi
are capable of inducing apoptosis not only in AML but also in
T- and B-cell-precursor-cell lines, providing a strong rationale
for evaluation of these substances in preclinical models of ALL.
Vorinostat and VPA also showed reduction of leukemic cell growth
in a NOD/SCID mouse model of childhood acute lymphoblastic
leukemia (Einsiedel et al., 2006). Furthermore, synergistic effects
of HDACi and DNMTi with conventional chemotherapy have
been shown and a combined pretreatment with vorinostat and
decitabine resulted in even greater cytotoxicity of chemotherapy
compared to each agent alone (Yang et al., 2005; Leclerc et al., 2010;
Bhatla et al., 2012). Data from adult trials show that HDACi, in
monotherapy as well as in combination therapy, are generally well
tolerated and similar results were obtained in a phase I study in
children and adolescents with solid tumors or leukemia (Fouladi
et al., 2010). Therefore, incorporation of these epigenetic agents to
the standard chemotherapy could be a promising approach to the
treatment of, e.g., relapsed pediatric acute lymphoblastic leukemia.
Most pediatric patients with very high risk leukemia or early
relapse after conventional chemotherapy will receive SCT. In sev-
eral studies it was shown that NK-mediated leukemia control plays
an important role after autologous and allogeneic transplantation
(Lowdell et al., 2002; Ruggeri et al., 2002; Leung et al., 2004).
Furthermore, reconstitution pattern of NK cell receptors and NK-
mediated cytotoxic activity were correlated to relapse rate after
haploidentical SCT in children (Pfeiffer et al., 2010; Lang et al.,
2011). Studies with several solid tumor entities and AML have
shown that treatment with HDACi and DNMTi could up regu-
late the expression of activating NK cell ligands, contributing to
an enhanced NK cell-mediated killing of the different tumor enti-
ties (Rohner et al., 2007; Diermayr et al., 2008; López-Soto et al.,
2009; Chávez-Blanco et al., 2011). Here, we showed that this effect
is not as pronounced in MHH-CALL-4 cells. MHH-CALL-4 cells
were either negative or only very low positive for the different
NKG2D-ligands. In contrast, we found higher expression of the
DNAM-1 ligands CD112 and CD155. This is in line with find-
ings from Pende et al. (2005) which obtained comparable results
on ALL blast from different patients and own unpublished results,
where leukemic blasts from 21 patients with precursor B-cell-acute
lymphoblastic leukemia were analyzed. NKG2D-ligands could not
be up regulated through incubation with vorinostat, VPA, azacy-
tidine, or decitabine. The expression level of the DNAM-1 ligand
CD112 could be further elevated by incubation with HDACi. The
leukemic cells could not be significantly sensitized to the lysis by
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FIGURE 5 | HDACi but not DNMTi reduce the NK-mediated lysis of
K562 and MHH-CALL-4 cells. Shown are mean values and standard
deviation from three independent assays with treated NK cells from healthy
donors against untreated K562 (A) and untreated MHH-CALL-4 (B)
(**p<0.01, ***p<0.005).
resting NK cells which can be due to high inter-individual variabil-
ity of different NK cell donors. Using IL-2 stimulated NK cells we
found a statistically significant effect for decitabine and a nearly
statistically significant effect for azacytidine (p= 0.06). A clear but
also not statistically significant effect was observed with HDACi
when using in vitro expanded NK cells as effectors. A limitation
of our study is the use of only one ALL cell line. Unfortunately,
primary blasts from our patients were not stable enough in culture
to investigate an effect of HDACi or DNMTi over 48 h.
Beside the effect on target cells, epigenetic drugs can also
affect the effector cells. In our experiments HDACi reduced the
NK-mediated lysis of both the standard NK target K562 and
MHH-CALL-4 cells and reduced the expression level of activat-
ing NK receptors on the cell surface. Comparable results against
K562 and other cell lines have been previously reported (Ogbomo
et al., 2007; Rossi et al., 2012). In contrast, DNMTi did not
significantly influence the NK-mediated lysis of K562 and MHH-
CALL-4 in our experiments. Different results have been published
by Schmiedel et al. (2011) showing a reduction of NK-mediated
lysis after incubation with azacytidine and an increase after incu-
bation with decitabine. The different observations could be due
to different incubation periods (24 vs. 48 h), different NK cell
preparation (expanded NK cells with IL-2 and RPMI 8866 feeder
cells vs. freshly isolated NK cells in our experiments). Also – as
in our experiments – there was great variability between differ-
ent NK donors and mean lysis of K562 without treatment was
clearly higher in the azacytidine experiments compared to the
decitabine experiments and hence maybe contributed to the dif-
ferent effect. On the other hand, the observed effect was also shown
for cytokine production. Recently published data from Kopp et al.
(2013) showed a significant inhibition of NK-mediated cytotox-
icity by decitabine at intermediate concentrations (0.1–2.5µM)
with a U -shaped dose response curve and only little effects at low
or high concentrations of decitabine. These findings could also
explain the different results obtained by different groups and sug-
gest further investigation in vivo to determine optimal dosages of
decitabine.
The diverse effects of the different epigenetic drugs on NK activ-
ity as well as the diverse effects of the same drugs with different NK
cell donors complicate recommendations for a clinical use. Espe-
cially in clinical situations where NK-mediated leukemia control
is assumed or wanted – like after haploidentical transplantation –
a sophisticated combination of single epigenetic drugs and, e.g.,
ex vivo expanded NK cells is needed to maximize the synergistic
effect of both treatment strategies and should be based on indi-
vidual testing. In this context, DNMTIs may be preferred due to
the stronger inhibitory effect of HDACi on NK cell cytotoxicity.
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